Beyond age: Frailty-guided care in hematologic malignancies.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41944130.
- Also identified by DOI 10.1002/cncr.70375.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Frailty, distinct from chronological age, reflects physiologic reserve and predicts toxicity, treatment discontinuation, and survival across hematologic malignancies. The authors synthesize contemporary frailty tools and summarize disease-specific evidence in multiple myeloma, acute myeloid leukemia, and aggressive lymphomas. Integrating frailty measures can inform shared decision-making and guide the management of vulnerable populations to enhance therapeutic benefit and optimize quality of life.
Medical subject headings
- Frailty
- Hematologic Neoplasms